Revenue Performance - Total revenues for Q3 2023 were $4,822 million, a 5% increase from $4,576 million in Q3 2022, with organic growth of 6%[161]. - For the nine months ended September 30, 2023, total revenues were $14,346 million, a 7% increase from $13,403 million in the same period of 2022, with organic growth of 9%[164]. - EMEA region revenues grew by 9% to $1,249 million in Q3 2023, driven by increases in Imaging, PDx, and PCS revenues[160]. - The China region saw revenues of $719 million, an 8% increase from $668 million in Q3 2022, despite unfavorable foreign currency impacts[160]. - Total revenues for the three months ended September 30, 2023, were $4,822 million, a 5% increase from $4,576 million in the same period of 2022[187]. Segment Performance - Product sales increased by 6% to $3,186 million in Q3 2023, driven by growth in Imaging, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS)[156]. - Imaging segment revenues reached $2,635 million, growing 5% year-over-year, supported by improvements in supply chain fulfillment and new product introductions[162]. - The Ultrasound segment reported revenues of $815 million, a slight decline of 1% from $823 million in Q3 2022, primarily due to prior year supply chain improvements[162]. - Imaging segment revenues were $7,751 million, growing 7% or $475 million, with organic revenue growth of 9% driven by MI/CT and MR product lines[1]. - Ultrasound segment revenues were $2,513 million, growing 2% or $47 million, with organic revenue growth of 4% primarily due to new product introductions[1]. - PCS segment revenues were $2,315 million, growing 9% or $185 million, with organic revenue growth of 10% across all product lines[1]. - PDx segment revenues were $1,715 million, growing 15% or $230 million, with organic revenue growth of 17% driven by improved demand[1]. Income and Expenses - Net income attributable to GE HealthCare for Q3 2023 was $375 million, down from $487 million in Q3 2022, reflecting a decrease of 23%[156]. - Operating income for Q3 2023 was $617 million, a 2% increase from $605 million in Q3 2022, but a decrease of 40 basis points as a percentage of total revenues[167]. - Total operating expenses increased by $150 million, with SG&A expenses rising by $88 million and R&D investments increasing by $62 million[169]. - Adjusted net income for the nine months ended September 30, 2023, was $1,258 million, a decrease of 17% from $1,507 million in the prior year[173]. - Adjusted net income for the three months ended September 30, 2023, was $451 million, a 17% decrease from $546 million in 2022[193]. Cash Flow and Debt - Free cash flow for the nine months ended September 30, 2023, was $759 million, a decrease of 10% compared to $841 million for the same period in 2022[198]. - Cash from operating activities for the nine months ended September 30, 2023, was $1,051 million, slightly down 1.9% from $1,071 million in 2022[203]. - Total debt as of September 30, 2023, was $10,260 million, an increase from $8,250 million as of December 31, 2022[216]. - Cash, cash equivalents, and restricted cash balance as of September 30, 2023, was $2,418 million, with access to revolving credit facilities totaling $3,500 million[199]. - Cash generated from financing activities was $422 million for the nine months ended September 30, 2023, compared to cash used of $785 million in 2022[209]. Research and Development - Research and development expenses increased to $322 million in Q3 2023, compared to $260 million in Q3 2022, marking a 24% rise[156]. - The company acquired Caption Health, an AI company, for $147 million, enhancing its capabilities in AI-guided ultrasound screening[207]. Earnings Per Share - Adjusted earnings per share for Q3 2023 was $0.99, down 17.5% from $1.20 in Q3 2022, and for the nine months ended September 30, 2023, it was $2.75, down 17.2% from $3.32 in the same period of 2022[195].

Financial Data and Key Metrics Changes - The company reported revenues of $4.8 billion for Q2 2023, representing a 7% increase year-over-year and a 9% organic growth, driven by strong product growth [21][22] - Adjusted EBIT margin was 14.8%, down 120 basis points year-over-year, primarily due to standalone costs and inflation, but improved 70 basis points sequentially from Q1 [19][52] - Adjusted EPS was $0.92, up 12% year-over-year on a standalone basis, but down 20% year-over-year due to interest expense [22] Business Line Data and Key Metrics Changes - Imaging segment saw a 9% year-over-year revenue growth, driven by molecular imaging CT and MR, although EBIT margin decreased by 380 basis points due to planned investments [55][56] - Patient Care Solutions (PCS) organic revenue grew by 9% year-over-year, driven by price and volume, with EBIT margin decreasing by 50 basis points due to inflation and planned investments [13][57] - Ultrasound generated 3% organic revenue growth year-over-year, reflecting high backlog fulfillment, with revenue driven by cardiovascular and women's health [12] Market Data and Key Metrics Changes - Global demand for healthcare products improved, with a 6% increase in orders in Q2, up from 3% in Q1 [18] - The company reported a healthy backlog of $18.4 billion, although it declined slightly due to revenues growing faster than orders [21][102] - Strong demand was noted in China, with revenue growth in double digits, as the country prioritizes improved healthcare access [53] Company Strategy and Development Direction - The company is focused on investing in AI and machine learning capabilities to enhance productivity and patient care, with a goal of creating interoperable ecosystems of devices and applications [5][26] - A balanced capital allocation strategy is being pursued, including organic investments, inorganic opportunities, deleveraging, and initiating dividends [20] - The company raised its full-year guidance for organic revenue growth to a range of 6% to 8% and adjusted EPS outlook to $3.70 to $3.85, reflecting confidence in market conditions [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the healthcare providers' continued investment globally, which is expected to drive demand for imaging and surgical equipment [4] - The company anticipates that many operational changes will yield benefits in 2024 and beyond, with a focus on margin expansion through productivity initiatives [11][60] - Management highlighted the importance of new product introductions and AI capabilities in driving future growth and improving patient outcomes [34][62] Other Important Information - The company is experiencing inflationary pressures and standalone costs that are impacting margins, but it is optimistic about future margin improvements through operational efficiencies [11][52] - The introduction of new AI technologies is expected to enhance product offerings and improve operational efficiency [62][110] - The company is well-positioned to capitalize on advancements in Alzheimer's disease therapies, which are expected to create new market opportunities [35][66] Q&A Session Summary Question: What is the status of the TSA roll-off and its impact on operating margins? - Management indicated that over 400 TSAs are to be exited over the next several years, with 100 already completed, which will positively impact operating margins in the coming years [41][42] Question: Can you elaborate on the order growth and market dynamics? - Management noted that order growth was strong at 6%, with a focus on maintaining mid-single-digit growth in the long term, despite some challenges in the market [49][80] Question: How does the company view the opportunity in Alzheimer's disease therapies? - Management expressed optimism about the growth opportunities related to new therapies and the company's role in providing diagnostic and monitoring solutions [66][99]

2Q 2023 Earnings Presentation This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outlook," and similar expressions. These forward-looking statements may include, but are not limited to, statements about our business; expected financial performance, inclu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) | Delaware | 88-2515116 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) | Delaware | 88-2515116 | ...

(Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street, Chicago IL 60661 (Address of principa ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) Q4 2022 Earnings Conference Call January 30, 2023 8:00 AM ET Company Participants Carolynne Borders - Chief Investor Relations Officer Peter Arduini - President and Chief Executive Officer Helmut Zodl - Vice President and Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Ed Ridley-Day - Redburn Vijay Kumar - Evercore Lawrence Biegelsen - Wells Fargo Veronika Dubajova - Citigroup Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Jaso ...

January 30, 2023 Forward-looking statements Product Status 4Q 2022 Earnings Presentation 2 Adjusted EBIT* & Adjusted EBIT margin* Adjusted EPS* Free cash flow* Book-to-Bill** 13% Organic growth*-a) $4.9B 17.1% margin (90) bps YoY Standalone Adjusted EBIT margin* of 16.1%-b) $844M Standalone Adjusted EPS* of ~$1.06-b) $1.31 $(0.05) YoY $436M YoY $987M 1.07x 4Q and Full Year 2022 Earnings Presentation © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. This presen ...